The EpiTer-2 database | Robert Flisiak, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Liver transplantation for HCV and HBV in The Czech Republic | Soña Frankova, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Clinical considerations in switching antiretroviral therapy | David Jilich, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Treatment-experienced patients in Central and Eastern Europe – What needs to be done? | Viktor Aster, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

HIV & women’s health: do we have any game changers here? | Mariana Mărdărescu, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Hepatitis Delta: what are the new developments, what are the challenges? | Cihan Yurdaydin, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Update on changes in Hepatitis B and C in CEE countries | Miłosz Parczewski, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Epidemiology of HIV Infection and Treatment in Europe | Teymur Noori, MSc

Central and Eastern European Meeting on Viral Hepatitis and HIV 2018

Novel delivery Systems - What's in the pipeline? | Courtney Fletcher, PharmD

European HIV Clinical Forum 2018

Long acting ARV for treatment and prevention - clinical considerations | Laura Waters, MD, FRCP

European HIV Clinical Forum 2018

Integrase Inhibitors in special patient populations | Sharon Walmsley, FRCPC, MD, MSC

European HIV Clinical Forum 2018

Switch strategies | Pedro Cahn, MD, PhD

European HIV Clinical Forum 2018

Reduced drug regimens - What are the Data? | José Arribas, MD

European HIV Clinical Forum 2018

Resistance to Integrase Inhibitors - What Clinicians Need to Know | Roger Paredes, MD, PhD

European HIV Clinical Forum 2018

One pill a day?: Integration novel delivery systems into routine care | Terry Blaschke, MD

Global HIV Clinical Forum 2018

Designing e-health interventions for HIV care | Guido van den Berk, MD, PhD

Global HIV Clinical Forum 2018

Clinical case: Integrase Inhibitors in Africa | Julia Turner, MD

Global HIV Clinical Forum 2018

Implication of the resent Dolutegravir data | Rebecca Zash, MD

Global HIV Clinical Forum 2018

What is the Virological support for reduced drug regimens? | Daniel Kuritzkes, MD

Global HIV Clinical Forum 2018

State of the ART: Integrase Inhibitors (clinical overview) | Mauro Schechter, MD, PhD

Global HIV Clinical Forum 2018

Future perspective for delivery of antiretroviral drugs | David Back, PhD

Rio de Janeiro HIV Clinical Forum 2018

Simplified regimens: pros and cons | Pedro Cahn, MD, PhD

Rio de Janeiro HIV Clinical Forum 2018

Clinical case presentation | Tânia Vergara, MD, PhD

Rio de Janeiro HIV Clinical Forum 2018

Optimal use of INSTI’s in routine practice | Carlos Brites, MD, PhD

Rio de Janeiro HIV Clinical Forum 2018